Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
The Company has completed the procedural requirements and dispatched the 'Letter of Confirmations' (LoCs) to the Shareholders as prescribed under SEBI Circular SEBI/ HO/ MIRSD/ MIRSD_RTAMB/ P/ CIR/ 2022/8 of January 25, 2022. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings call pertaining to the Financial Results for the quarter ended June 30, 2022 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Unaudited Financial Results for the quarter ended June 30, 2022
Stride Pharma Science Q1 net loss narrows to Rs 163 cr, revenue grows 36.6%
Strides Pharma Science Ltd on Friday reported a narrowing of consolidated net loss at Rs 163.4 crore in the quarter ended June 2022, aided by higher revenue Q1FY23 Quarterly Result Announced for Strides Pharma Science Ltd.
Pharmaceuticals firm Strides Pharma Science Announced Q1FY23 Result : Strides reports an improved Q1FY23 with visible growth momentum Consolidated revenues at Rs 9,457m up 37% YoY Consolidated EBITDA at Rs 657m up 100%+ YoY with healthy EBITDA margin expansion Key businesses deliver steady performance, cost control measures yielding results Levers in place to deliver a strong performance in FY23 with improved profitability and a stronger balance sheet Commenting on the performance, Arun Kumar, Founder, Managing Director, and Executive Chairperson remarked, “We have started the new fiscal on a healthy note. Our strategy is now gaining traction across the front-end and partner-led businesses. Our customer engagement and strong order inflows give us confidence for even a more robust near-term performance as we progress forward. The US business has maintained growth during the quarter. However, Chestnut Ridge portfolio customer transition led to a spill of $5m to the current quarter. Adjusted for the same, the revenues in the US were at $51m with the adjusted consolidated EBITDA at ~ Rs 820m. The transition completed on 21st July and we are confident of a healthy ramp-up for the US business driven by improved performance in the base business and new launches from the combined portfolio of approved products to meet our stated growth outlook in the US. Although the Other Regulated markets witnessed a sequential decline due to currency headwinds, the long term outlook for the business remains steady. Our Emerging markets maintained the business trend, and we remain invested in the opportunity. One of the key drivers for performance this year will be our focus on cost controls. I am pleased to share that we are tracking to the plan on our control programs, and some of the major decisions taken over the last few months have started to yield savings. We remain aggressive on cost curtailment, including a significant focus around our manufacturing network optimization. With all levers in place, we are confident to deliver a strong performance in FY23 with significantly improved profitability and a stronger balance sheet.” Result PDF Strides Pharma Science Ltd - 532531 - Grant Of Options Under Strides ESOP Plan 2016
Grant of Options under Strides ESOP Plan 2016 Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended June 30, 2022
Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2022 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter ended June 30, 2022. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Raising of Funds
Outcome of Meeting of the Committee of the Board of Directors of the Company held on Monday, July 25, 2022 Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Friday, July 29, 2022, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2022, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Friday, July 1, 2022, upto Sunday, July 31, 2022 (both days inclusive). This is for your kind information and record purposes.